8-K: Intelligent Bio Solutions Executes 1-for-10 Reverse Stock Split

Intelligent Bio Solutions Inc. announced a 1-for-10 reverse stock split to become effective on December 15, 2025, aiming to adjust its share structure.

Summary

• Intelligent Bio Solutions Inc. will effect a one-for-ten (1-for-10) reverse stock split of its common stock.
• Stockholders approved an amendment to the Certificate of Incorporation for a reverse stock split on October 16, 2025, and the Board of Directors approved the 1-for-10 ratio on December 12, 2025.
• The amendment to the Certificate of Incorporation was filed with the Secretary of State of Delaware on December 12, 2025.
• The reverse stock split will become effective at 11:59 p.m. Eastern Time on December 15, 2025.
• Common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the open of trading on December 16, 2025, under the existing symbol INBS and a new CUSIP number (36151G709).
• The number of outstanding common shares will be reduced from approximately 9,595,335 shares as of December 14, 2025, to approximately 959,533 shares immediately following the split.
• The par value per share will remain $0.01, and the number of authorized shares of common stock will remain at 100 million.
• No fractional shares will be issued; instead, cash payments will be made based on the average closing sale prices for the five consecutive trading days immediately preceding the split date on Nasdaq.
• Proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise or vesting of outstanding stock options, restricted stock unit awards, and warrants, as well as shares reserved under the 2019 Plan.

Sentiment

Score: 4

Explanation: A reverse stock split is generally viewed with caution by investors as it often indicates a company's stock price has fallen significantly, potentially below exchange minimums. While it can help maintain listing compliance and potentially attract institutional investors, it does not fundamentally change the company's valuation or operational performance and can sometimes lead to reduced liquidity or further price declines if underlying issues are not addressed.

Positives

• None explicitly stated in the filing.

Negatives

• Post-split, the basic loss per share for the 12 months ended June 30, 2025, will increase from $(2.00) to $(20.04).
• Post-split, the diluted loss per share for the 12 months ended June 30, 2025, will increase from $(2.00) to $(20.04).
• Post-split, the basic loss per share for the 12 months ended June 30, 2024, will increase from $(6.38) to $(63.77).
• Post-split, the diluted loss per share for the 12 months ended June 30, 2024, will increase from $(6.38) to $(63.77).
• Post-split, the basic loss per share for the three months ended September 30, 2025, will increase from $(0.35) to $(3.49).
• Post-split, the diluted loss per share for the three months ended September 30, 2025, will increase from $(0.35) to $(3.49).
• Post-split, the basic loss per share for the three months ended September 30, 2024, will increase from $(0.70) to $(7.05).
• Post-split, the diluted loss per share for the three months ended September 30, 2024, will increase from $(0.70) to $(7.05).

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions' public filings with the U.S. Securities and Exchange Commission.

Future Outlook

Forward-looking statements in this release include, without limitation, statements regarding Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory approvals, among others. However, actual results may differ materially from expectations due to known and unknown risks and uncertainties.

Industry Context

Intelligent Bio Solutions Inc. operates as a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions, particularly its Intelligent Fingerprinting Drug Screening System. Reverse stock splits are a common corporate action across various industries, often undertaken to adjust share price and structure, which can be influenced by broader market conditions or company-specific performance.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are provided to assess the reverse stock split in the context of global benchmarks. Reverse stock splits are a corporate finance tool used across various industries, typically to address low stock prices or meet exchange listing requirements, rather than a direct comparison of operational performance.

Corporate Governance

Stakeholder Impact

• Shareholders will hold fewer shares, but their percentage ownership in the company will remain the same, except for those receiving cash for fractional shares.
• The per-share price is expected to increase proportionally, potentially helping the company meet Nasdaq's minimum bid price requirements.
• The change in share structure may impact market perception and trading liquidity.

Next Steps

• Common stock will begin trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market at the open of trading on December 16, 2025.
• Shareholders will receive cash in lieu of fractional shares.
• Outstanding equity-based awards and other equity rights will be proportionately adjusted.

Key Dates

Keywords

Intelligent Bio Solutions, INBS, reverse stock split, stock split, Nasdaq, common stock, corporate action, medical technology, drug screening, fingerprinting